A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 5, 2012, Pages 515-523

  Daull, Philippe ^a   Buggage, Ronald ^a   Lambert, Grégory ^a   Faure, Marie Odile ^a   Serle, Janet ^b   Wang, Rong Fang ^b   Garrigue, Jean Sébastien ^a  

^a Novagali Pharma   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; CATIOPROST; LATANOPROST; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CROSSOVER PROCEDURE; DRUG INSTILLATION; DRUG SAFETY; FEMALE; GLAUCOMA; HAPLORHINI; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRABECULAR MESHWORK;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CATIONS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; EYE; FEMALE; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; RABBITS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84867002915     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0245     Document Type: Article

References (29)

1. Sharts-Hopko, N.C., and Glynn-Milley, C. Primary openangle glaucoma. Am. J. Nurs. 109:40-47, quiz 48, 2009.
2. Toris, C.B., Gabelt, B.T., and Kaufman, P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 53 Suppl 1:S107-S120, 2008.
3. Honrubia, F., Garcia-Sanchez, J., Polo, V., Martinez-dela-Casa, J.M., and Soto, J. Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a metaanalysis of randomized clinical trials. Br. J. Ophthalmol. 93: 316-321, 2009.
4. Stjernschantz, J., Selen, G., Astin, M., and Resul, B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog. Retin. Eye Res. 19:459-496, 2000.
5. Baudouin, C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 86:716-726, 2008.
6. Baudouin, C., Liang, H., Hamard, P., Riancho, L., Creuzot-Garcher, C., Warnet, J.M., and Brignole-Baudouin, F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both Thelper 1 and T-helper 2 pathways. Ophthalmology 115:109-115, 2008.
7. Liang, H., Baudouin, C., Pauly, A., and Brignole-Baudouin, F. Conjunctival and corneal reactions in rabbits following short-and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol. 92:1275-1282, 2008.
8. Baudouin, C., Labbe, A., Liang, H., Pauly, A., and Brignole-Baudouin, F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 29:312-334, 2010.
9. Wilson, W.S., Duncan, A.J., and Jay, J.L. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br. J. Ophthalmol. 59:667-669, 1975.
10. Herreras, J.M., Pastor, J.C., Calonge, M., and Asensio, V.M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99:1082-1088, 1992.
11. Leung, E.W., Medeiros, F.A., and Weinreb, R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma 17:350-355, 2008.
12. Hommer, A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. Drugs Today (Barc). 46:409-416, 2010.
13. Lallemand, F., Daull, P., Benita, S., Buggage, R., and Garrigue, J.S. Successfully improving ocular drug delivery using the cationic nanoemulsion Novasorb. J. Drug Deliv. 2012. Article ID 604204, doi:10.1155/2012/604204.
14. Serle, J.B., Podos, S.M., Kitazawa, Y., and Wang, R.F. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn. J. Ophthalmol. 42:95-100, 1998.
15. Hubert, P., Nguyen-Huu, J.J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.A., Dewe, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N, Muzard, G., Nivet, C., and Valat, L. Validation of quantitative analytical procedure, harmonization of approaches. STP Pharma Pratiques 13:101-138, 2003.
16. Hubert, P., Nguyen-Huu, J.J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.A., Dewe, W., Feinberg, M., Lallier, M., Laurentie, M., Mercier, N., Muzard, G., Nivet, C., and Valat, L. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal-part I. J. Pharm. Biomed. Anal. 36:579-586, 2004.
17. Hubert, P., Nguyen-Huu, J.J., Boulanger, B., Chapuzet, E., Cohen, N., Compagnon, P.A., Dewe, W., Feinberg, M., Laurentie, M., Mercier, N., Muzard, G., Valat, L., and Rozet, E. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal-part III. J. Pharm. Biomed. Anal. 45:82-96, 2007.
18. Aiache, J.M., el Meski, S., Beyssac, E., and Serpin, G. The formulation of drug for ocular administration. J. Biomater. Appl. 11:329-348, 1997.
19. Sjoquist, B., Basu, S., Byding, P., Bergh, K., and Stjernschantz, J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab. Dispos. 26:745-754, 1998.
20. Gipson, I.K. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 48:4390-4398, 2007.
21. Royle, L., Matthews, E., Corfield, A., Berry, M., Rudd, P.M., Dwek, R.A., and Carrington, S.D. Glycan structures of ocular surface mucins in man, rabbit and dog display species differences. Glycoconj. J. 25:763-773, 2008.
22. Samuelson, D. Ophthalmic anatomy. In: Gelatt, K., ed. Veterinary Ophthalmology. Philadelphia: Lippincott Williams & Wilkins; 1999; p. 31-150.
23. Liang, H., Baudouin, C., Faure, M.O., Lambert, G., and Brignole-Baudouin, F. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol. Vis. 15:1690-1699, 2009.
24. Liang, H., Baudouin, C., Daull, P., Garrigue, J.S., and Brignole-Baudouin, F. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models. Cornea 2012 (In press).
25. Erb, C., Gast, U., and Schremmer, D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 246: 1593-1601, 2008.
26. Rossi, G.C., Tinelli, C., Pasinetti, G.M., Milano, G., and Bianchi, P.E. Dry eye syndrome-related quality of life in glaucoma patients. Eur. J. Ophthalmol. 19:572-579, 2009.
27. Mundorf, T.K. Treat glaucoma patients globally. Adv. Ocular Care 9:71-72, 2011.
28. Godfrey, D.A. Glaucoma: what's next? Ophthalmol. Times. 10:42-43, 2011.
29. Abelson, M.B., and Lafond, A. Glaucoma and dry eye: a tough combo. Rev. Ophthalmol. 11:108-111, 2011.